Practical Insights on Using BCMA-Targeted Therapies in Multiple Myeloma
Decera Clinical Education Oncology Podcast
00:00
The Importance of Real World Data in CAR-T Cell Therapy
The outcome of patients with renal insufficiency receiving CAR-T cell treatment is the same. We've seen that even patients on dialysis can benefit from the strategy. CRS or cytokine release syndrome when typically soon after the patient is given the drug sometimes within minutes to hours that they experience this response, this immune response, go cytokine release Syndrome. Patients can experience neurotoxicity either in the short term or the long term and we've seen some differences between these molecules. Then perhaps one that we initially didn't appreciate quite the magnitude of it was the risk of infections both in the shortterm and the long term.
Play episode from 18:14
Transcript
